Next Update Pending, page-61

Agree with what you about Sonic’’s characteristics as an investment @Gindaldan, but am more positive than you are about the recent acquisition of Pathology Watch.

I can’t claim to understand the applicable technology, but it sounds like a desirable step towards digital pathology and AI, and Sonic’s assets should complement it nicely (apparently). You’re right, it’s not yet profitable, but it’s only costing 1.5% of market cap and the financial benefits are medium term. I’m actually pleased management is taking a long term view of things.

I doubt it impacted the share price much, as it’s a relatively small bolt on, although I respect that you might have been watching that more closely than I did and drew your conclusion accordingly. Anyway, hopefully in 5 years time we might look back on the Pathology Watch purchase and say it was a good move, albeit initially profit less.